| Bone marrow transplantation from unrelated donors for patients with adult T-cell leukaemia/lymphoma. | |
| | |
MedLine Citation:
|
PMID: 16247419 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Adult T-cell leukaemia/lymphoma (ATLL) is a highly aggressive haematological malignancy. More than 40 cases of ATLL treated by allogeneic bone marrow transplantation (BMT) from sibling donors have been reported, while there have been only a few cases of unrelated BMT for treatment of this disease. We began performing allogeneic BMT from unrelated donors in 1999 to improve the outcome of ATLL patients with no suitable sibling donors. Eight ATLL patients underwent unrelated BMT; five received the conventional conditioning regimen consisting of cyclophosphamide and total body irradiation, while three received a reduced-intensity preparative regimen. Two patients died due to encephalopathy of unknown aetiology on days 10 and 35, and one patient died due to progression of ATLL 25 months after BMT. Five patients are currently alive and disease-free at a median of 20 months after BMT. Proviral human T-lymphotropic virus type-I (HTLV-I) DNA load in peripheral blood mononuclear cells (PBMCs) was assessed in four cases before and after BMT. HTLV-I proviral DNA load was reduced significantly after transplantation. Unrelated BMT is feasible for treatment of ATLL. Further studies in a larger number of cases are required to determine the optimal conditioning regimen and stem cell source. |
| | |
Authors:
|
K Nakase; M Hara; T Kozuka; K Tanimoto; Y Nawa |
Related Documents
:
|
20496989 - Allogeneic hematopoietic stem cell transplant following chemotherapy containing l-aspar... 17891639 - Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive b-cell ... 12030999 - Allogeneic bone marrow transplant improves outcome for juvenile myelomonocytic leukaemia. 11328309 - Graft-versus-host disease and survival after abo-incompatible allogeneic bone marrow tr... 11253609 - Lymphoblastic lymphoma. 7581149 - Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells afte... 21477939 - Role of principal component analysis in predicting toxicity in prostate cancer patients... 18024399 - Melphalan-induced dna damage in vitro as a predictor for clinical outcome in multiple m... 21263089 - Future directions in the treatment of neuroendocrine tumors: consensus report of the na... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Bone marrow transplantation Volume: 37 ISSN: 0268-3369 ISO Abbreviation: Bone Marrow Transplant. Publication Date: 2006 Jan |
Date Detail:
|
Created Date: 2005-12-16 Completed Date: 2006-04-05 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8702459 Medline TA: Bone Marrow Transplant Country: England |
Other Details:
|
Languages: eng Pagination: 41-4 Citation Subset: IM |
Affiliation:
|
Division of Hematology, Ehime Prefectural Central Hospital, Matsuyama City, Ehime, Japan. nakase.koichi@nifty.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Bone Marrow Transplantation* Cyclophosphamide / administration & dosage Disease-Free Survival Female Histocompatibility Testing Humans Leukemia-Lymphoma, Adult T-Cell / blood, mortality, therapy* Living Donors* Male Middle Aged Myeloablative Agonists / administration & dosage Retrospective Studies Transplantation Conditioning* Transplantation, Homologous Whole-Body Irradiation / methods |
| Chemical | |
Reg. No./Substance:
|
0/Myeloablative Agonists; 50-18-0/Cyclophosphamide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Low CXCR4 membrane expression on CD34(+) cells characterizes cells mobilized to blood.
Next Document: Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women af...